Abbott India
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Abbott India is currently navigating a pivotal transition under new leadership, focusing on chronic and sub-chronic care, gastrointestinal, and CNS segments. Management's strategic pivot towards organic brand building and potential inorganic partnerships is crucial for long-term growth, especially as the company capitalizes on favorable demographics and increasing healthcare awareness in India. However, challenges such as margin compression from reinvestment needs and heightened competition in mature categories could impact earnings. Vista's financial outlook reflects stable revenue growth consistent with historical performance, supported by a conservatively financed balance sheet and stable profit margins. The current valuation aligns with intrinsic value, indicating limited upside potential. Industry dynamics, including improving pricing power and a robust pipeline of innovative products, provide a supportive backdrop, although margin pressures persist. Over the next 12-24 months, key opportunities include expanding into higher-margin products and leveraging export growth, while watchpoints include regulatory compliance and competitive intensity in core segments
Why We Like This Stock
- Management's strategic pivot towards chronic care and operational efficiency enhances long-term growth prospects
- Stable revenue growth and profit margins align with historical performance, supported by a conservatively financed balance sheet
- Favorable industry dynamics, including improving pricing power and a strong pipeline of innovative products, bolster the company's outlook
Things To Watch Out For
- Margin compression due to reinvestment needs and intense competition in mature categories poses risks to earnings
- Regulatory and compliance challenges may impact operational efficiency and investor sentiment
- Limited upside potential in valuation suggests constrained market performance in the near term
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 5,849 | 6,409 | 6,929 | 6,953 | 7,643 |
| Profit Before Tax (Cr.) | 1,618 | 1,888 | 2,079 | 2,193 | 2,381 |
| PBT Margin | 27.7% | 29.5% | 3000.4% | 31.5% | 31.2% |
| Net Profit (Cr.) | 1,202 | 1,408 | 1,535 | 1,626 | 1,766 |
| Earnings Per Share | 565.7 | 662.8 | 722.1 | 765.3 | 831.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BOB Capital Markets | ▲ Buy | 36,457 | 13-May-2026 |
| ICICI Securities | ▲ Buy | 32,550 | 13-Aug-2026 |
| JPMorgan | ► Hold | 27,500 | 15-Apr-2026 |
Company Overview
Show Company Profile
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.